Abstract. integrins mediate the interaction of cells with the extracellular matrix and are believed to be involved in tumor cell survival and metastasis, and in tumor angiogenesis. We used immunohistochemistry of fresh-frozen human tumor tissues to analyze the presence of integrins αvβ3, αvβ5 and α5β1, which are believed to be involved in tumor growth and migration, together with integrin ligands, vitronectin, osteopontin, fibronectin and fibrinogen, in human oral squamous cell carcinomas. Samples of squamous cell carcinomas and control tissues from patients without cancer undergoing oral or maxillofacial surgery were frozen in liquid nitrogen within 30 min of removal. Frozen sections were prepared, and the presence of integrins or ligands was visualized using standard immunohistochemistry (apaap) with a blinded evaluation. comparison of samples from the 40 oral cancer patients and the 20 controls revealed increased staining in tumors compared with the controls, and staining was demonstrated for αvβ3 in endothelia. αvβ5 staining was increased in the tumor samples, but this was associated with increased expression in stroma rather than in endothelia. modestly increased expression of α5β1 was observed in the tumor samples, and this was associated with tumor cells, endothelia and stroma. Expression of ligands for the integrins varied between tissue types, with increased fibrinogen and fibronectin expression in tumor endothelia. Confirmation of the presence of these integrins and their association with tumor cells, endothelia or stroma suggests their potential for these integrins in human oral tumors. Overall, the increased expression of integrins within tumors, particularly expression associated with endothelial cells, supports the principle of selective integrin blockade as a novel anticancer strategy.
Introduction
Worldwide, the 5-year survival rate for patients with squamous cell carcinoma of the head and neck (HNSCC) has not significantly increased for many years (1) (2) (3) (4) (5) . HNSCC is diagnosed predominantly at the age range of 50-70 years, but is also observed in younger patients (6) (7) (8) . despite aggressive initial management of the primary tumor, locoregional recurrence occurs in some 60% of cases, and distant metastasis is observed in some 25%. therefore, innovative therapeutic concepts are urgently required.
angiogenesis is essential for tumor progression and metastasis. tumor angiogenesis is complex and involves crosstalk between tumor-derived growth factors, the modified extracellular matrix that develops around tumors, and endothelial receptors for extracellular matrix and growth factors (9, 10) . inhibition of angiogenesis often suppresses the tumor growth of model tumors, and the suppression and eradication of malignant tumors by targeting angiogenetic endothelial cells is a rapidly evolving approach to cancer therapy (10, 11) . Such therapies might influence highly vascularized head and neck cancers (12) (13) (14) (15) (16) (17) , simOn l. GOOdman 3 and Jan-dirK raGusE strategies (9, (18) (19) (20) (21) (22) (23) . in particular, the integrins, αvβ3, αvβ5 and α5β1, have been implicated in tumor angiogenesis. inhibitors of these integrins are being investigated in clinical trials (9, (19) (20) (21) (24) (25) (26) , and we previously reported a signal in an hnscc patient when using an αvβ3/αvβ5 inhibitor (27) . integrin action depends on the presence of complementary ligands. While αvβ5 and α5β1 are conservative in their ligand binding, being essentially monospecific for vitronectin and fibronection, respectively, αvβ3 binds promiscuously to numerous matrix components. The ligands fibrinogen and osteopontin rather monospecifically target αvβ3 (28) . vitronectin is a common serum component activated by conformational change (29); the activated molecule is detected immunologically (30) . in the present study, we evaluated the expression of integrins, αvβ3, αvβ5 and α5β1, and their ligands, fibrinogen (αvβ3, α5β1), fibronectin (αvβ3, α5β1), osteopontin (αvβ3) and activated vitronectin (αvβ3, αvβ5), in head and neck cancer and control tissues.
Materials and methods
Patients. Samples of squamous cell carcinomas from 40 patients (32 male, 8 female) were obtained during oral or maxillofacial surgery. control non-cancerous tissues containing squamous epithelium were obtained from 20 patients undergoing outpatient surgical procedures (tables i and ii). patients provided informed consent for the collection of samples, and all tissues examined were taken from the head and neck area with previous consent of the patients in our clinic in the context of diagnostics and therapy.
Tumor samples and sample preparation. the tissue samples were stored in isotonic saline for 15-30 min immediately following removal from patients. all tissues were cut into pieces with an edge length of ~4 mm, embedded in freezing medium (leica instrument, nussloch) in a plastic tube, shock-frozen for 2 min in liquid nitrogen, and cryopreserved at -80˚C until sectioning. A cryomicrotome (CM3000; Leica instrument) was used to prepare 4-to 6-µm sections, which were placed on coated slides (superFrost plus, menzel, Braunschweig or Dako, Denmark), air-dried for ~12 h at 20˚C, and stored frozen in a dry atmosphere usually at -80˚C (occasionally -20˚C).
Frozen sections were thawed, air-dried, and fixed for 15 min in fresh dry acetone at -20˚C. Experience revealed that this method provides clearer and stronger staining compared to fixing with methyl alcohol-acetone (9 min methanol and 1 min acetone at -20˚C). All fixed sections were incubated with blocking buffer x0909 (ready-to-use; dako) for 20 min to reduce non-specific staining. Samples were incubated with primary antibodies for 60 min. table iii lists the antibodies and dilution used. Optimal dilutions of antibodies were identified in preliminary experiments and were then used throughout the study.
an alkaline phosphatase-anti-alkaline phosphatase (apaap) system was used to visualize the bound antibody (31) . slides were rinsed three times with tris-wash buffer, ph 7.6, (dako s3001) and incubated for 40 min with a bridging antibody diluted 1:40. sections incubated with monoclonal antibodies (table iii) were incubated with polyclonal rabbit anti-mouse bridging antibody (dako Z02259), and sections incubated with polyclonal antibodies were incubated with monoclonal mouse anti-rabbit bridging antibody (dako m0737), diluted with the antibody diluent (dako s2022) plus 5% ab serum (biotest aG, cat. no. 805135) in each case. sections were washed again three times in tbs buffer and then incubated for 40 min with the monoclonal apaap complex (dako d0651) diluted 1:100 in antibody diluent plus 5% inactivated fetal calf serum (biochrom s0115). after thorough rinsing, the subsequent substrate development was carried out for over 20 min with the substrate (dako 070524) containing two drops of levamisole (dako K5000). after further rinsing, counterstaining was carried out using hemalaun (dako s2020) for 5 min followed by bluing for 5 min in tap water.
For optimum recognition of squamous cell carcinoma in the small frozen sections, we used a monoclonal antibody against proliferation marker Ki-67 (dako, m7240, clone mib-1) and a monoclonal antibody against the adhesion molecule cd44v6 (bender bms116, clone vFF-7), performing the same immunohistochemical apaap method as previously (32) (33) (34) . although this was effective, we did not use the synopsis of score values for the expression of Ki-67 and cd44v6. vessel densities were routinely assessed using cd31 staining including score values.
Evaluation of expression with immunoreactivity scores
and number of vessels. the evaluation of immunoreactivity scores (IHS) was carried out using x200 magnification as described (32) (33) (34) (35) . sections were evaluated three times including an evaluation by a tumor pathologist in a blinded manner. staining intensity (si) was assessed according to a categorical scale: 0, no staining; 1, faint staining; 2, slight staining; 3, moderate staining; and 4, strong staining. the percentage of positively stained cells (pp) was assessed as: 0, no positive cells; 1, 0-25% positive cells; 2, 26-50% positive cells; 3, 51-75% positive cells; and 4, 76-100% positive cells. an overall ihs was derived by multiplying the staining intensity (si) by the percentage of positive staining or the staining frequency (PP) scores (range of possible scores 0-16). Staining of glands, muscle, histiocytes and inflammatory cells was ignored. in no instances were single cells counted in the tumors or in the squamous epithelium samples.
an additional parameter was used in the third microscopic evaluation with assessment of the number of vessels. this involved quantitative estimation of the number of marked vessels using a lower magnification (x100). Using antibodies (table iii), we distinguished the estimated numbers of marked vessels in the tumors (or squamous epithelium in controls) and stroma: scale 0, no vessels; scale 1, isolated vessels; scale 2, few vessels; scale 3, numerous vessels; and scale 4, large quantities of vessels. First, the highest possible vessel density was visualized using the antibody directed at the 'typical' endothelial marker, cd31, followed by visualization of other antigens of interest using the antibodies described in table iii.
Statistics. pasW statistics for Windows (version 18.0.0) was used for statistical evaluation, with a cut-off for significance of p<0.05. the t-test was used when the values were distributed normally, and most often with the mann-Whitney u-test for non-normally distributed data (36) .
Results
Samples analyzed. tumor samples (n=40) (table i) were from the floor of the mouth (n=18), the tongue or tongue plus the floor of the mouth (n=11), the oropharynx (n=3) and the alveolar process, gingiva, or planum buccale (n=8). according to pathologic tnm tumor staging, approximately half of the tumors were t4 (n=21) with the remainder distributed among t3 (n=6), t2 (n=9) and t1 (n=4); in each case tumors were fairly evenly distributed among n0-n3, and m status was not available. Overall stage grouping identified 27 samples as s4, 7 as s3, 4 as s2 and 2 as s1; 14 tumors were grade 3, 23 were grade 2 and 3 were grade 1. control samples (n=20) (table ii) were from the tongue (n=3), the A B C the mean ihs for αvβ5 and α5β1 integrins in tumor cells were significantly higher than those from the control samples of squamous epithelium ( Fig. 1a ; Tables IV and v); this resulted from higher si and pp scores for αvβ5 and from a higher si score for α5β1 ( Fig. 1b ). higher average si and pp scores contributed to these differences in intensity of expression (table iv) . lower mean ihs were observed for integrins αvβ5 and α5β1, and osteopontin and vitronectin (table iv and Fig. 1 ) with no clear differences between tumor samples and control tissues (αvβ5, p=0.590; α5β1, p=0.223; osteopontin, p=0.544; vitronectin, p=0.634; u-test) (table v) .
all three integrins were more strongly and statistically significantly expressed in tumor stroma compared to stroma of control squamous epithelia (U-test; p<0.001) ( Fig. 1c ; Table IV and v), mainly as a result of higher si scores for αvβ5 and α5β1, and by higher si and pp scores for αvβ3. however, αvβ3 was less strongly expressed than αvβ5 and α5β1, as judged by the overall ihs. Osteopontin was not strongly expressed, although the ihs was higher in tumor stroma vs. the control (ihs 3.0 vs. 1.1; p<0.001). activated vitronectin was expressed weakly at similar levels in the normal and tumor stroma. Fibrinogen (IHS 15.7 vs. 15.2; p=0.082) and fibronectin (ihs 15.5 vs. 13.8; p=0.029) were strongly expressed in the tumor and control samples, while the expression of cd31 was low and similar between the tumors and controls (ihs 2.4 vs. 2.1; p=0.325). Table I ) with a tumor of the alveolar process, x200 magnification. T, tumor; v, vessel; st, stroma. Quantification of blood vessels in the tumors and control epithelia or stroma in both tissues. integrin expression in the blood vessels of the tumor tissues and in stroma were evaluated separately with a maximal score of 4.0 (Fig. 3) . using a typical marker of endothelial cells, cd31, immunostaining revealed a higher density of endothelial cells in the tumors vs. the control tissues (1.9 vs. 0.8; p=0.099; u-test), with a higher or similar density of staining in tumor stroma and control samples (tumor stroma 2.6 vs. stroma in control tissues 2.3; p=0.173; u-test) ( Fig. 3 ; tables vi and vii). integrins were more strongly expressed on endothelia within the tumor tissue than in the control squamous epithelium, although a clear difference between tumor and control samples was observed only for integrin αvβ3 (table vi; Fig. 3 ). Endothelial cells in the stroma expressed integrins more strongly than in the tumor tissue. the number of vessels, when compared between the tumor and control samples in the stroma, was greater in the tumor tissues for αvβ3 and statistically significant (p=0.012, Table VII) compared to the other integrins (αvβ3, 1.7 vs. 1.2; αvβ5, 1.2 vs. 1.0; α5β1, 1.0 vs. 0.8) (Table VI) . Fibrinogen and fibronectin were expressed strongly in the tumor tissue and tumor stroma and their respective control tissues, with mean ihs generally comparable with those for CD31 (tumor tissues vs. controls: fibrinogen, 1.5 vs. 1.1; fibronectin, 1.7 vs. 0.9; CD31, 1.9 vs. 0.8; and in tumor stroma vs. controls: fibrinogen, 2.0 vs. 1.4; fibronectin, 1.9 vs. 1.5; cd31, 2.6 vs. 2.3) (table vi). Osteopontin was expressed less strongly with little difference in expression between the tumors and control samples for tumor tissue or stroma (tumor tissues vs. controls: 0.5 vs. 0.7 and tumor stroma vs. controls: 0.9 vs. 0.7). Tumor endothelia expressed fibronectin and fibrinogen more strongly than control endothelia, while staining for vitronectin and osteopontin expression was unchanged over the control. Fig. 1 . p-values determined using the u-test.
----------------------------------------------------------------------------------------------------------------------

Discussion
integrins interacting with their complementary extracellular matrix targets regulate normal cellular behavior. changes in these interactions are implicated in cancer progression (23, (37) (38) (39) (40) (41) . in this study, we used immunohistochemistry to investigate the expression of integrin-ligand combinations implicated in tumor angiogenesis within tumor material from 40 hnssc patients compared to 20 normal controls. We investigated αvβ3, αvβ5, α5β1 and their ligands, osteopontin, Table VI . Contribution of the quantitative estimate of the number of vessels in the tumor tissues or in squamous epithelium of the controls and in stroma, respectively. a vessels in vessels in stroma of vitronectin, fibronectin and fibrinogen, and found that these proteins are disregulated within the tumor environment. αvβ5 and α5β1 were overexpressed in tumor cells, αvβ3 in endothelia, and each integrin in the tumor stroma. Expression of the ligands, fibrinogen and fibronectin, was elevated in the tumor vasculature environment, fibronectin and osteopontin in the stroma, but none in the tumor cells, while activated vitronectin remained unchanged in each environment. these results support a role for αvβ3-osteopontin and fibronectin, α5β1-fibronectin interactions in influencing HNSCC angiogenesis and α5β1-fibronectin and αvβ5-vitronectin influencing tumor cell behavior. The elevated fibrinogen and fibronectin in the vasculature may be related to defective vascular patency and increased serum leakage within tumors. vitolo et al (39) detected an increasing frequency of α5β1 expression in oral tissues; expression in 0/7 normal epithelium, in carcinoma in situ 8/9 and in invasive carcinoma 8/13, in contrast to lack of expression of αvβ3 in the same tissues. according to thomas and speight (40) , the integrin α5β1 was weakly expressed in oral keratinocytes, while αvβ6 was implicated in hnscc progression (42) . in the in vitro study of reinartz et al (43) , αvβ5 was expressed in human keratinocytic cells (hacat). in epithelia of the controls we found that each of the three integrins, αvβ3, αvβ5 and α5β1, was expressed; αvβ3 exhibited the weakest expression (table iv) . Expression of αvβ3 remained weak in normal epithelia, but was significantly higher than in the tumor tissues (Table V) . however, in our study the epithelia of the controls exhibited weak expression of α5β1 and significantly lower α5β1 expression than in the tumor tissues.
increased or inappropriate expression of integrins is believed, in coordination with their ligands, to support tumor growth and metastasis, and to promote tumor angiogenesis in head and neck carcinomas (37) (38) (39) (40) (41) 44, 45) . these phenomena are of considerable scientific and clinical interest, as experimental studies indicate that disruption of integrin function may inhibit the growth, neovascularization and metastasis of some types of cancers (9, (19) (20) (21) (22) (23) . indeed, drugs that block the interaction of integrins with the extracellular matrix are under development for the management of several clinically important tumor types. One such drug, cilengitide, is a selective blocker of ligand interaction with αvβ3 and αvβ5 integrins (9, 18, 24, 25, 27) : the integrins assessed in this study.
We demonstrated marked expression of integrins and their ligands in oral tumor tissues (table iv), and strong staining for cd31 in tumor tissues was consistent with angiogenesis and neovascularization (table iv and Fig. 2h ), thus confirming observations in oral cancer by Kurtz et al (15) and villaret et al (46) . in our study we found weak staining for αvβ3 in tumor or stromal cells (table iv and Fig. 2a) . this is in contrast to observations noted in malignant gliomas by schnell et al (47) and in melanoma by albelda et al (48) , who found that tumors expressed higher levels of αvβ3 than normal tissues. A statistically significant increased staining vs. controls was demonstrated for αvβ3 in endothelia, but not in stroma (tables iv and v). in the present study, αvβ5 staining was statistically significantly increased in tumor samples compared to the controls (table v), which corroborates the findings of Jones et al (37) . however, αvβ5 was markedly expressed in stroma rather than in endothelia. there was some increase in the expression of α5β1 in tumor samples associated with tumor cells, endothelia and stroma. Expression of ligands for integrins varied between the tissue types, with no clear differentiation and no statistically significant expression between tumor and control samples, with the notable exception of the αvβ3 ligand osteopontin and the αvβ3/α5β1 ligand fibronectin, which were significantly up-regulated in the tumor stroma. this complements the up-regulation of αvβ3 and α5β1 noted on the tumor vasculature. notably, since activated vitronectin was conspicuously uniformly distributed between the normal and tumor tissues, it appears to be less involved in tumor-specific integrin-driven behaviors in HNSCC.
Previous histochemical studies identified the expression of αvβ3 in various tumors, with a particularly strong and functional association with tumor invasive blood vessels consistent with the more detailed analyses of the present study (49) (50) (51) (52) . Other studies have found increased αvβ3 expression to be correlated with greater invasive or metastatic potential (53) (54) (55) . Radiotracers specific to αvβ3 have revealed this integrin in human tumor tissue in situ (47, 56) . αvβ5 integrin has also been implicated in tumor cell invasion and migration (57) (58) (59) , and αvβ3 and αvβ5 regulate cellular responses to hypoxia in glioblastomas (60) . α5β1 has also been implicated in tumor migration and angiogenesis (61) (62) (63) (64) (65) and may control cell migration in concert with αvβ3 (66) .
Confirmation of the presence of integrins, αvβ3 and αvβ5, and their activating ligands in association with hnscc tumors, supports a potential role for these integrins in human oral tumors. Overall, increased expression of integrins within tumors, particularly expression associated with endothelial cells, supports the emergent therapeutic concept of selective integrin blockade as a anticancer strategy (9, 23, 27, 67) .
